An Bio Analytical Method for the Simultaneous Estimation of Favipiravir and Remdesivir in Rat Plasma by LCMS/MS

Estimation of Favipiravir and Remdesivir in Rat Plasma by LCMS/MS

Abstract

Objectives: FDA approved and antiviral drugs of Favipiravir and Remdesivir were used in the treatment of covid. For the bio analytical approach of Favipiravir and Remdesivir, quick and easy, exact, active and repeatable LC-MS/MS methodology were created, employing D₅-Favipiravir and D₅-Remdesivir as internal standards.

Methods: In this study, A Symmetry C₁₈ column (150 mm x 4.6mm, 3.5µm) was used for separation, with an elution by isocracy using a 1mL formic acid-filled buffer in a 1lit involving liquid and a 50:50 combination of mobile phase consisting of buffer and acetonitrile with 1 mL/min flow rate at room temperature.

Results: Favipiravir (r² = 0.9999) was tested across a reasonable concentration According to USFDA requirements, we discovered that the medications remained stable throughout the stability trials, just because the validated approach has successfully conducting to the pharmacokinetic studies of two drugs.

Conclusion: It is concluded that if both drugs are used in combination, they may produce a beneficial effect in the treatment of Covid-19 patients.